280 related articles for article (PubMed ID: 30727891)
1. Anti-Virulence Strategy against the Multidrug-Resistant Bacterial Pathogen Pseudomonas aeruginosa: Pseudolysin (Elastase B) as a Potential Druggable Target.
Galdino ACM; de Oliveira MP; Ramalho TC; de Castro AA; Branquinha MH; Santos ALS
Curr Protein Pept Sci; 2019; 20(5):471-487. PubMed ID: 30727891
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic insights into elastin degradation by pseudolysin, the major virulence factor of the opportunistic pathogen Pseudomonas aeruginosa.
Yang J; Zhao HL; Ran LY; Li CY; Zhang XY; Su HN; Shi M; Zhou BC; Chen XL; Zhang YZ
Sci Rep; 2015 Apr; 5():9936. PubMed ID: 25905792
[TBL] [Abstract][Full Text] [Related]
3. High-level expression of pseudolysin, the extracellular elastase of Pseudomonas aeruginosa, in Escherichia coli and its purification.
Odunuga OO; Adekoya OA; Sylte I
Protein Expr Purif; 2015 Sep; 113():79-84. PubMed ID: 25979480
[TBL] [Abstract][Full Text] [Related]
4. Blue light treatment of Pseudomonas aeruginosa: Strong bactericidal activity, synergism with antibiotics and inactivation of virulence factors.
Fila G; Kawiak A; Grinholc MS
Virulence; 2017 Aug; 8(6):938-958. PubMed ID: 27763824
[TBL] [Abstract][Full Text] [Related]
5. Identification of residues in the Pseudomonas aeruginosa elastase propeptide required for chaperone and secretion activities.
McIver KS; Kessler E; Ohman DE
Microbiology (Reading); 2004 Dec; 150(Pt 12):3969-77. PubMed ID: 15583150
[TBL] [Abstract][Full Text] [Related]
6. Virulence attributes in Brazilian clinical isolates of Pseudomonas aeruginosa.
Silva LV; Galdino AC; Nunes AP; dos Santos KR; Moreira BM; Cacci LC; Sodré CL; Ziccardi M; Branquinha MH; Santos AL
Int J Med Microbiol; 2014 Nov; 304(8):990-1000. PubMed ID: 25127423
[TBL] [Abstract][Full Text] [Related]
7. Binding Mode Characterization and Early in Vivo Evaluation of Fragment-Like Thiols as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa.
Kany AM; Sikandar A; Haupenthal J; Yahiaoui S; Maurer CK; Proschak E; Köhnke J; Hartmann RW
ACS Infect Dis; 2018 Jun; 4(6):988-997. PubMed ID: 29485268
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitors of the Pseudomonas aeruginosa virulence factor LasB: a potential therapeutic approach for the attenuation of virulence mechanisms in pseudomonal infection.
Cathcart GR; Quinn D; Greer B; Harriott P; Lynas JF; Gilmore BF; Walker B
Antimicrob Agents Chemother; 2011 Jun; 55(6):2670-8. PubMed ID: 21444693
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the DsbA oxidative folding catalyst from Pseudomonas aeruginosa reveals a highly oxidizing protein that binds small molecules.
Shouldice SR; Heras B; Jarrott R; Sharma P; Scanlon MJ; Martin JL
Antioxid Redox Signal; 2010 Apr; 12(8):921-31. PubMed ID: 19788398
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa virulence proteins pseudolysin and protease IV impede cutaneous wound healing.
Prasad ASB; Shruptha P; Prabhu V; Srujan C; Nayak UY; Anuradha CKR; Ramachandra L; Keerthana P; Joshi MB; Murali TS; Satyamoorthy K
Lab Invest; 2020 Dec; 100(12):1532-1550. PubMed ID: 32801335
[TBL] [Abstract][Full Text] [Related]
11. Subinhibitory concentrations of phenyl lactic acid interfere with the expression of virulence factors in Staphylococcus aureus and Pseudomonas aeruginosa clinical strains.
Chifiriuc MC; Diţu LM; Banu O; Bleotu C; Drăcea O; Bucur M; Larion C; Israil AM; Lazăr V
Roum Arch Microbiol Immunol; 2009; 68(1):27-33. PubMed ID: 19507624
[TBL] [Abstract][Full Text] [Related]
12. Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections.
Juan C; Peña C; Oliver A
J Infect Dis; 2017 Feb; 215(suppl_1):S44-S51. PubMed ID: 28375513
[TBL] [Abstract][Full Text] [Related]
13. [Pseudomonas aeruginosa virulence factors as a therapeutic target in multidrug-resistant strains].
Nováková K; Kolář M
Klin Mikrobiol Infekc Lek; 2023 Mar; 29(1):11-19. PubMed ID: 37586087
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of virulence factors in multidrug-resistant Pseudomonas aeruginosa strains.
Deptuła A; Gospodarek E
Arch Microbiol; 2010 Jan; 192(1):79-84. PubMed ID: 19960337
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design of α-Substituted Mercaptoacetamides as Inhibitors of the Virulence Factor LasB from
Kaya C; Walter I; Alhayek A; Shafiei R; Jézéquel G; Andreas A; Konstantinović J; Schönauer E; Sikandar A; Haupenthal J; Müller R; Brandstetter H; Hartmann RW; Hirsch AKH
ACS Infect Dis; 2022 May; 8(5):1010-1021. PubMed ID: 35451824
[TBL] [Abstract][Full Text] [Related]
16. Virulence Factors of
Liao C; Huang X; Wang Q; Yao D; Lu W
Front Cell Infect Microbiol; 2022; 12():926758. PubMed ID: 35873152
[No Abstract] [Full Text] [Related]
17. Chimeric Protein-Protein Interface Inhibitors Allow Efficient Inhibition of Type III Secretion Machinery and
Ngo TD; Plé S; Thomas A; Barette C; Fortuné A; Bouzidi Y; Fauvarque MO; Pereira de Freitas R; Francisco Hilário F; Attrée I; Wong YS; Faudry E
ACS Infect Dis; 2019 Nov; 5(11):1843-1854. PubMed ID: 31525902
[No Abstract] [Full Text] [Related]
18. Molecular Insights into Function and Competitive Inhibition of
Kitao T; Lepine F; Babloudi S; Walte F; Steinbacher S; Maskos K; Blaesse M; Negri M; Pucci M; Zahler B; Felici A; Rahme LG
mBio; 2018 Jan; 9(1):. PubMed ID: 29339431
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the machinery that introduces disulfide bonds in Pseudomonas aeruginosa.
Arts IS; Ball G; Leverrier P; Garvis S; Nicolaes V; Vertommen D; Ize B; Tamu Dufe V; Messens J; Voulhoux R; Collet JF
mBio; 2013 Dec; 4(6):e00912-13. PubMed ID: 24327342
[TBL] [Abstract][Full Text] [Related]
20. The rapid
Wang K; Chen YQ; Salido MM; Kohli GS; Kong JL; Liang HJ; Yao ZT; Xie YT; Wu HY; Cai SQ; Drautz-Moses DI; Darling AE; Schuster SC; Yang L; Ding Y
Open Biol; 2017 Sep; 7(9):. PubMed ID: 28878043
[No Abstract] [Full Text] [Related]
[Next] [New Search]
